Treatment regimens for rifampicin-resistant tuberculosis: highlighting a research gap

H R Stagg; H-A Hatherell; M C Lipman; Ross J Harris; I Abubakar

doi:10.5588/ijtld.16.0034

Treatment regimens for rifampicin-resistant tuberculosis: highlighting a research gap

H R Stagg, H-A Hatherell, M C Lipman, Ross J Harris, I Abubakar

Research output: Contribution to journal › Article › peer-review

Abstract / Description of output

Treatment guidance for non-multidrug-resistant (MDR) rifampicin-resistant (RMP-R) tuberculosis (TB) is variable. We aimed to undertake a systematic review and meta-analysis of the randomised controlled trial (RCT) data behind such guidelines to identify the most efficacious treatment regimens. Ovid MEDLINE, the Web of Science and EMBASE were mined using search terms for TB, drug therapy and RCTs. Despite 12 604 records being retrieved, only three studies reported treatment outcomes by regimen for patients with non-MDR RMP-R disease, preventing meta-analysis. Our systematic review highlights a substantial gap in the literature regarding evidence-based treatment regimens for RMP-R TB.

Original language	English
Pages (from-to)	866-9
Number of pages	4
Journal	International Journal of Tuberculosis and Lung Disease
Volume	20
Issue number	7
DOIs	https://doi.org/10.5588/ijtld.16.0034
Publication status	Published - Jul 2016

Keywords / Materials (for Non-textual outputs)

Antibiotics, Antitubercular/therapeutic use
Biomedical Research/methods
Drug Resistance, Bacterial
Evidence-Based Medicine
Humans
Microbial Sensitivity Tests
Predictive Value of Tests
Professional Practice Gaps/methods
Randomized Controlled Trials as Topic
Rifampin/therapeutic use
Tuberculosis/diagnosis

Access to Document

10.5588/ijtld.16.0034

Cite this

@article{3264545d10c749ec819d7a65c48ee649,

title = "Treatment regimens for rifampicin-resistant tuberculosis: highlighting a research gap",

abstract = "Treatment guidance for non-multidrug-resistant (MDR) rifampicin-resistant (RMP-R) tuberculosis (TB) is variable. We aimed to undertake a systematic review and meta-analysis of the randomised controlled trial (RCT) data behind such guidelines to identify the most efficacious treatment regimens. Ovid MEDLINE, the Web of Science and EMBASE were mined using search terms for TB, drug therapy and RCTs. Despite 12 604 records being retrieved, only three studies reported treatment outcomes by regimen for patients with non-MDR RMP-R disease, preventing meta-analysis. Our systematic review highlights a substantial gap in the literature regarding evidence-based treatment regimens for RMP-R TB.",

keywords = "Antibiotics, Antitubercular/therapeutic use, Biomedical Research/methods, Drug Resistance, Bacterial, Evidence-Based Medicine, Humans, Microbial Sensitivity Tests, Predictive Value of Tests, Professional Practice Gaps/methods, Randomized Controlled Trials as Topic, Rifampin/therapeutic use, Tuberculosis/diagnosis",

author = "Stagg, {H R} and H-A Hatherell and Lipman, {M C} and Harris, {Ross J} and I Abubakar",

year = "2016",

month = jul,

doi = "10.5588/ijtld.16.0034",

language = "English",

volume = "20",

pages = "866--9",

journal = "International Journal of Tuberculosis and Lung Disease",

issn = "1027-3719",

publisher = "International Union Against Tuberculosis and Lung Disease",

number = "7",

}

TY - JOUR

T1 - Treatment regimens for rifampicin-resistant tuberculosis: highlighting a research gap

AU - Stagg, H R

AU - Hatherell, H-A

AU - Lipman, M C

AU - Harris, Ross J

AU - Abubakar, I

PY - 2016/7

Y1 - 2016/7

N2 - Treatment guidance for non-multidrug-resistant (MDR) rifampicin-resistant (RMP-R) tuberculosis (TB) is variable. We aimed to undertake a systematic review and meta-analysis of the randomised controlled trial (RCT) data behind such guidelines to identify the most efficacious treatment regimens. Ovid MEDLINE, the Web of Science and EMBASE were mined using search terms for TB, drug therapy and RCTs. Despite 12 604 records being retrieved, only three studies reported treatment outcomes by regimen for patients with non-MDR RMP-R disease, preventing meta-analysis. Our systematic review highlights a substantial gap in the literature regarding evidence-based treatment regimens for RMP-R TB.

AB - Treatment guidance for non-multidrug-resistant (MDR) rifampicin-resistant (RMP-R) tuberculosis (TB) is variable. We aimed to undertake a systematic review and meta-analysis of the randomised controlled trial (RCT) data behind such guidelines to identify the most efficacious treatment regimens. Ovid MEDLINE, the Web of Science and EMBASE were mined using search terms for TB, drug therapy and RCTs. Despite 12 604 records being retrieved, only three studies reported treatment outcomes by regimen for patients with non-MDR RMP-R disease, preventing meta-analysis. Our systematic review highlights a substantial gap in the literature regarding evidence-based treatment regimens for RMP-R TB.

KW - Antibiotics, Antitubercular/therapeutic use

KW - Biomedical Research/methods

KW - Drug Resistance, Bacterial

KW - Evidence-Based Medicine

KW - Humans

KW - Microbial Sensitivity Tests

KW - Predictive Value of Tests

KW - Professional Practice Gaps/methods

KW - Randomized Controlled Trials as Topic

KW - Rifampin/therapeutic use

KW - Tuberculosis/diagnosis

U2 - 10.5588/ijtld.16.0034

DO - 10.5588/ijtld.16.0034

M3 - Article

C2 - 27287636

SN - 1027-3719

VL - 20

SP - 866

EP - 869

JO - International Journal of Tuberculosis and Lung Disease

JF - International Journal of Tuberculosis and Lung Disease

IS - 7

ER -

Treatment regimens for rifampicin-resistant tuberculosis: highlighting a research gap

Abstract / Description of output

Keywords / Materials (for Non-textual outputs)

Access to Document

Fingerprint

Cite this